🔗 Share this article

As America continues making sweeping revisions to its immunization guidelines, an unexpected name has surfaced in a surprising turn: Høeg, a US-based sports medicine doctor and epidemiologist who initially gained attention by questioning COVID-19 vaccinations during the global health crisis and has focused upon alleged fatalities following Covid immunization in her recent position at the Food and Drug Administration.

Scheduled Changes to Pediatric Immunization Program

Agency leaders planned to announce major changes to the childhood vaccine schedule in December, bringing the US with Denmark’s vaccine program, sources say – a substantial departure that would place the US out of alignment with many the world with little proof for benefit. This reveal has been delayed until the next year.

Rather than the top vaccines chief, Tracy Beth Høeg is scheduled to present at the event. She was recently named acting director of the FDA’s CDER, the fifth person to lead the division this calendar year.

Consolidating Power at the FDA

The acting appointment could signify a closer partnership between the pharmaceutical and vaccine divisions as Høeg and Dr. Prasad solidify control at the regulatory agency – and it points to a greater focus upon reevaluating already-approved immunizations at the FDA.

The new acting director has frequently advocated for discontinuing certain childhood vaccine recommendations in the US so as to align more similar to Denmark's approach, a country with universal health coverage and a citizenry approximately the population of the state of Wisconsin.

To date comments, she has kept her attention on immunizations – traditionally the responsibility of Prasad, head of the FDA’s vaccine center – rather than drug regulation.

Doubts Over Qualifications

The appointee has little discernible background in pharmaceutical research, regulation or leadership, which has been standard for former leaders of the CBER. She has served at the FDA as a key advisor to the commissioner and the vaccine center since March.

“She doesn’t seem to have any of the qualifications” for leading the pharmaceutical oversight division, remarked a neurologist and psychiatrist. “She lacks experience running a scientific study. She has no expertise in running a sizeable institution. She has no expertise in industry regulation.”

Past directors of CBER would “be deeply familiar with laws and regulations and the research of drug development”, noted Janet Woodcock. “Clearly, she has not acquired the sort of resume that prior appointees who headed the center have had.”

This division has an vast portfolio at the FDA, the former commissioner emphasized.

“Everybody just focuses on the novel medication approvals, but the generic drug division clears thousands of off-brand pharmaceuticals. There’s a biosimilars division, OTC medication office and other areas, and every single one have to be supervised,” Woodcock said. “The thing you don’t keep your eye on, that is precisely what that I always told people is going to bite you.”

There is also, a substantial management element to the job, which oversees more than 5,000 staff members. “It is a huge leadership role, if you execute it properly,” Woodcock concluded.

Response and Contentious Programs

When asked about questions about Høeg’s fitness for the role and whether this selection signifies greater collaboration among agency officials on immunizations, a spokesperson said that the “questions rely on inaccurate assumptions”.

“Her resume aligns with the functions of her job,” the official said, pointing to the period Dr. Høeg spent advising the FDA commissioner on “pharmaceutical safety and oversight research, including predictive safety algorithms and vaccine surveillance”.

As the temporary head, Dr. Høeg takes over the commissioner’s controversial priority voucher program, a controversial expedited drug-approval program that reportedly troubled her predecessors. “By what process are these therapies being picked for this voucher program? Who makes the choices?” Howard asked. “There is a lot of confidentiality going on at the FDA right now.”

Overall, he said, “the agency appears to be shifting towards less stringent regulations of pharmaceuticals, with the exception of immunizations.”

Established History on Vaccines

Concerning immunizations, Dr. Høeg has a clearer, if problematic, history, some experts said. She authored a study using non-validated crowd-sourced reports to assess the rate of myocarditis following COVID-19 vaccination. She consulted for the Florida top health official Joseph Ladapo, who allegedly have changed statistics to suggest Covid vaccines are riskier than they are.

Among her “policy goals” for the current federal leadership encompassed changing rules for novel immunizations and discontinuing “non-essential” immunizations, she stated post-election on a online show. At the FDA, Dr. Høeg has reportedly proposed barring teenage boys from receiving Covid vaccinations.

“She is an complete true believer who starts off with her conclusions and reverse-engineers to retrofit the science in a very misleading, untruthful way,” Dr. Howard said.

Gaining Influence and a “Push for Payback”

Dr. Høeg became part of fellow skeptics, {like|